How India Exports Morphine to the World

In the United States, morphine is a well-established analgesic with numerous approved Abbreviated New Drug Applications (ANDAs). The FDA's Orange Book lists multiple generic formulations, indicating a competitive market landscape. Recent approvals include generic versions of extended-release morphine sulfate tablets, enhancing accessibility for patients. The regulatory pathway for morphine involves stringent evaluation of bioequivalence and adherence to Good Manufacturing Practices (GMP). Notably, the presence of 16 active Indian exporters underscores India's significant role in supplying morphine to the U.S. market.

In the European Union, the European Medicines Agency (EMA) oversees the approval and monitoring of morphine-containing products. Marketing authorizations are granted following comprehensive assessments of quality, safety, and efficacy. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) maintains similar standards, ensuring that morphine products meet stringent regulatory requirements. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers, ensuring consistent product quality across member states.

Morphine has been included in the WHO Model List of Essential Medicines since its first edition in 1977, underscoring its critical role in pain management. The 24th edition, published in September 2025, continues to list morphine as an essential medicine. This inclusion emphasizes the necessity of morphine's availability in healthcare systems worldwide. Additionally, morphine formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy.

In India, morphine is classified under Schedule X of the Drugs and Cosmetics Act, indicating its status as a controlled substance due to potential abuse. The National Pharmaceutical Pricing Authority (NPPA) regulates the ceiling price of morphine to ensure affordability; the latest revision was implemented in January 2026. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC), ensuring compliance with international narcotics control regulations.

Morphine, being a long-established pharmaceutical compound, is not subject to active patents, allowing for extensive generic competition. This competitive environment contributes to the widespread availability and affordability of morphine products globally.

In June 2023, the World Health Organization (WHO) published a report titled "Left behind in pain: Extent and causes of global variations in access to morphine for medical use and actions to improve safe access," highlighting disparities in morphine availability and proposing strategies for improvement. (who.int)

In September 2025, the WHO released the 24th edition of the Model List of Essential Medicines, reaffirming morphine's status as an essential medicine for pain management. (who.int)

These developments underscore the ongoing global efforts to enhance access to morphine, address regulatory challenges, and ensure its safe and effective use in pain management.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% are from India. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact India's API production capabilities. For instance, in October 2025, the U.S. Pharmacopeia highlighted that 58% of KSMs used for U.S.-approved APIs are sole-sourced from a single country, underscoring the vulnerability in the supply chain.

To mitigate these risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, aiming to promote domestic manufacturing of critical KSMs, DIs, and APIs. As of September 2025, this initiative has led to the establishment of manufacturing capacity for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. However, the scheme's focus has been on APIs like Meropenem and Ritonavir, with no specific mention of morphine-related APIs, indicating a potential gap in addressing the supply chain risks associated with morphine production.

The export market for morphine from India is highly concentrated, with the top five exporters accounting for 95.5% of the market share. MEDWISE OVERSEAS PRIVATE LIMITED alone holds a 64.8% share, followed by VENOR PHARMA LIMITED at 24.5%. This high level of supplier concentration poses a significant single-source risk; any operational disruptions within these key companies could severely impact the global supply of morphine.

While the PLI Scheme for Bulk Drugs has made strides in reducing import dependency for certain APIs, its current focus does not encompass morphine-related APIs. This oversight leaves the morphine supply chain vulnerable to disruptions, emphasizing the need for targeted initiatives to diversify and strengthen the supplier base for morphine exports.

Global shipping routes, particularly the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceuticals. Any geopolitical tensions or conflicts in these regions can lead to shipping delays and increased costs. Additionally, ongoing U.S.-China trade tensions have the potential to disrupt the supply of KSMs and APIs, further impacting India's pharmaceutical manufacturing.

The U.S. Food and Drug Administration (FDA) has issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP). In February 2025, the FDA highlighted cGMP violations by Global Calcium, an Indian API manufacturer, including failures in quality control and data integrity. Such regulatory actions can lead to supply shortages and emphasize the need for stringent quality control measures within the supply chain.

• Diversify Supplier Base: Encourage the development of additional suppliers for morphine exports to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Expand the PLI Scheme to include morphine-related APIs, promoting domestic manufacturing and reducing reliance on imported KSMs.

• Strengthen Quality Control: Implement rigorous quality assurance protocols to ensure compliance with international standards, mitigating the risk of regulatory actions.

• Monitor Geopolitical Developments: Establish a dedicated task force to assess and respond to geopolitical events that may impact shipping routes and raw material availability.

• Develop Alternative Shipping Strategies: Identify and establish alternative shipping routes and logistics partners to ensure continuity in the supply chain during geopolitical disruptions.

RISK_LEVEL: MEDIUM